Durable Response of Metastatic Tumor to Erlotinib and Capecitabine in a Patient with Pancreatic Adenocarcinoma

對得舒緩和截瘤達有耐久性反應的胰臟癌

郭哲銓(Jhe-Cyuan Guo) ； 陳若白(Jo-Pai Chen)

《台灣癌症醫學雜誌》 29卷3期 (2013/08) Pp. 155-159

https://doi.org/10.6323/JoCRP.2013.29.3.7

摘要

胰臟癌併遠處轉移是一個令人沮喪的診斷。我們報告一個74歲的早期肺癌病人在接受根除性手術治療一年後又得到胰臟癌。病人接受胰臟癌手術治療，但手術後不久就發現多處轉移。病人接受幾線的化學治療後疾病仍然持續惡化，直到erlotinib合併化學治療使用，病情才得到長期控制。病人已只使用erlotinib和capecitabine，就維持有效反應近兩年。我們回顧了K-RAS 突變和erlotinib對胰臟癌患者的療效之間的關係。

關鍵字

胰臟癌 ； 得舒緩 ； K-RAS基因

並列摘要

Pancreatic adenocarcinoma with distant metastases is an extremely challenging diagnosis. We report on a 74-year-old man with early stage lung cancer who had previously received a curative operation. Subsequent pancreatic cancer developed one year later. A curative operation for pancreatic cancer was then performed, but rapid tumor recurrence with multiple metastatic sites were identified soon after the operation. The patient was treated with several lines of chemotherapy but progressive disease persisted until erlotinib-combined chemotherapy was undertaken. Then the patient maintained a durable response to erlotinib and capecitabine for nearly 2 years. We reviewed the relationship between K-RAS mutation and the efficacy of erlotinib on pancreatic adenocarcinoma.

並列關鍵字

pancreatic adenocarcinoma ； erlotinib ； K-RAS